<DOC>
	<DOCNO>NCT01715350</DOCNO>
	<brief_summary>The investigator intend perform exploratory evaluation treatment effectiveness safety PM012 Tablet PuriMED Co. , Ltd. 2 dos Korean patient mild moderate dementia Alzheimer 's type . To achieve , study aim compare dose placebo control efficacy safety explore clinically optimal dose PM012 Tablet therapeutic confirmatory ( phase 3 ) clinical study .</brief_summary>
	<brief_title>Study Explore Optimal Dosage/Administration Alzheimer 's Disease</brief_title>
	<detailed_description>1 . Period study -48 month date KFDA approval protocol 2 . Study subject -Patients mild moderate Alzheimer 's disease 3 . Study objectives 1 . Primary objective - To compare efficacy 2 dos PM012 Tablet placebo base cognitive effect assess ADAS-cog Week 12 post-dose 2 . Secondary objective - To compare efficacy 2 dos PM012 Tablet placebo base cognitive effect assess ADAS-cog Week 8 post-dose - To compare efficacy 2 dos PM012 Tablet placebo base overall functional effect assess CDR Weeks 8 12 post-dose - To compare efficacy 2 dos PM012 Tablet placebo base activity daily live assess K-IADL Weeks 8 12 post-dose - To compare efficacy 2 dos PM012 Tablet placebo base behavioral change assess NPI Weeks 8 12 post-dose - To compare efficacy 2 dos PM012 Tablet placebo base cognitive effect assess K-MMSE Weeks 8 12 post-dose - To compare efficacy 2 dos PM012 Tablet placebo base improvement VAS assess Senile Dementia Pattern Identification Diagnosis System Weeks 8 12 post-dose 4 . Study drug / Comparator -650-mg PM012 Tablet PuriMED Co. , Ltd. / Placebo 5 . Dosage/ Administration Method administration 1 . Placebo group - Morning : Placebo 2T , Evening : Placebo 2T 2 . Dose group 1 - Morning : Placebo 1T+Study drug 1T , Evening : Placebo 1T+Study drug 1T 3 . Dose group 2 - Morning : Study drug 2T , Evening : Study drug 2T 4 . Study drug 650-mg PM012 tablet 5 . The drug take water within 30 minute breakfast supper . 6 . Even meal take , dose omit drug take enough amount water . 6 . Treatment duration -12 week 7 . Number subject 1. placebo group - Efficacy population:42 , Drop-out ( 20 % ) included:53 2 . Dose group 1 - Efficacy population:42 , Drop-out ( 20 % ) included:53 3 . Dose group 2 - Efficacy population:42 , Drop-out ( 20 % ) included:53 4 . Total - Efficacy population:126 , Drop-out ( 20 % ) included:159 8 . Study method - This study design multicenter , randomize , double-blind , parallel placebo group 2 dose group , phase 2 clinical study patient dementia Alzheimer 's type age ≥ 50 ≤ 85 year . - Once subject voluntarily provide write consent participate study , he/she randomized meeting inclusion criterion exclusion criterion screen test . Randomized subject receive study drug placebo 12 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 ) Male female patient age ≥ 50 ≤ 85 year 2 ) Clinically diagnose probable Alzheimer 's disease base DSMIV NINCDSADRDA criterion 3 ) KMMSE score 12~26 screen visit 4 ) For female : 2 year confirm menopause surgical sterilization . 5 ) Able walk ( include use aid ) 6 ) Able perform procedure cognitive test 7 ) Residing lifelong guardian willing accompany subject 's visit , oversee his/her compliance procedure specify protocol study drug , report his/her condition . 8 ) Having sign him/herself his/her legally acceptable representative sign write informed consent form 1 ) Possible , probable , definite vascular dementia NINDSAIREN criterion 2 ) History and/or evidence ( result CT MRI perform within past 12 month screen ) CNS disease ( cerebrovascular disease , structural developmental anomaly , epilepsy , contagious , degenerative infectious/demyelinating CNS condition ) cause dementia 3 ) Delusion , delirium , epilepsy neurological pathology neurological examination 4 ) Abnormal test result vitamin B12 , syphilis serology , thyroid stimulate hormone ( TSH ) test think contribute subject 's dementia severity cause dementia 5 ) History significant psychiatric disease schizophrenia bipolar affective disorder may interfere participation study opinion investigator , current depression ( GDS ≥ 18 ) 6 ) Past history know suspected seizure include febrile convulsion , unexplained recent unconsciousness past history significant head trauma unconsciousness . 7 ) Gastrointestinal , endocrine cardiovascular disease control diet pharmacologic therapy 8 ) Cardiac disease myocardial infarction valvular disease heart , arrhythmia within 3 month study start 9 ) Diabetes mellitus control hypoglycemic agent insulindependent diabetes mellitus 10 ) Past history alcohol drug abuse 11 ) Having take acetylcholinesterase inhibitor memantine within past 3 month 12 ) Hypertension systolic blood pressure &gt; 165 mmHg diastolic blood pressure &gt; 96 mmHg 13 ) Severe renal impairment ( serum creatinine ≥ 1.7 mg/dl ) 14 ) Severe hepatic impairment ( ALT , AST , bilirubin ≥ 2.0 x upper limit normal ) 15 ) Is take expected take disallow concomitant medication 16 ) History clinically significant drug hypersensitivity 17 ) Is ineligible participate study judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>